Logen: Medgend

BOSULIF [Bosutinib Monohydrate^{C₂₆H₂₉Cl₂N₅O₃H₂O}]

RX

-

eq 100mg base (oral tablet)

eq 500mg base (oral tablet)

Pf Prism Cv^{Sep 4, 2012}

A method of treating a neoplasm.
A method of treating chronic myelogenous leukemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE [Atropine Sulfate^{2C₁₇H₂₃NO₃H₂OH₂O₄S} : Diphenoxylate Hydrochloride^{C₃₀H₃₂N₂O₂ClH}]

RX

-

0.025mg/5ml : 2.5mg/5ml (oral solution)

0.025mg : 2.5mg (oral tablet)

West-ward Pharms Int^{May 3, 1982}
Ani Pharms Inc^{Approved Prior To Jan 1, 1982}
Lannett^{Approved Prior To Jan 1, 1982}
Mylan^{Approved Prior To Jan 1, 1982}
Par Pharm^{May 2, 2000}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

ICLUSIG [Ponatinib Hydrochloride^{C₂₉H₂₇F₃N₆OClH}]

RX

-

eq 15mg base (oral tablet)

eq 30mg base (oral tablet)

eq 45mg base (oral tablet)

Ariad^{Dec 14, 2012}

A method for the treatment of leukemias.
A method for treating acute lymphoblastic leukemia.
A method for treating chronic myeloid leukemia.
A method for treating leukemia resulting from a mutation in the bcr-abl kinase domain.
A method for treating philadelphia chromosome positive acute lymphoblastic leukemia.
A method of treating chronic myelogenous leukemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

LOMOTIL [Atropine Sulfate^{2C₁₇H₂₃NO₃H₂OH₂O₄S} : Diphenoxylate Hydrochloride^{C₃₀H₃₂N₂O₂ClH}]

RX

-

0.025mg : 2.5mg (oral tablet)

Gd Searle Llc^{Approved Prior To Jan 1, 1982}

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

MYFORTIC [Mycophenolic Acid^{C₁₇H₂₀O₆}]

RX

-

180mg (oral tablet, delayed release)

360mg (oral tablet, delayed release)

Novartis^{Feb 27, 2004}

Prophylaxis of organ rejection in patients receiving allogeneic renal transplants.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

SPRYCEL [Dasatinib^{C₂₂H₂₆ClN₇O₂SH₂O}]

RX

-

100mg (oral tablet)

140mg (oral tablet)

20mg (oral tablet)

50mg (oral tablet)

70mg (oral tablet)

80mg (oral tablet)

Bristol Myers Squibb^{May 30, 2008}

A method for the treatment of a protein tyrosine kinase-associated disorder.
A method for the treatment of cancer.
A method for treatment of a cancer, wherein the cancer is chronic myelogenous leukemia.

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

SYNRIBO [Omacetaxine Mepesuccinate^{C₂₉H₃₉NO₉}]

RX

-

3.5mg/vial (subcutaneous powder)

Teva Pharms Intl^{Oct 26, 2012}

Treatment of leukemia.
Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml).

efficacy
0.0 (0)

side effects
0.0 (0)

danger
0.0 (0)

TRISENOX [Arsenic Trioxide^As₂O₃]

RX

-

1mg/ml (injection injectable)

Cephalon^{Sep 25, 2000}

Treatment of acute promyelocytic leukemia (apl) in patients whose apl is characterized by the presence of the (15;17) translocation or pml/rar-alpha gene expression.
Treatment of acute promyelocytic leukemia (apl).
Treatment of acute promyelogenous leukemia (apl).

Ledgend of Medicine

MODERN MEDICINES

HOME REMEDIES

RANDOM DRUGS

RANDOM AILMENTS

Logen FDA Approved Drugs